Executive Director, Market Access GI, Europe

Revolution Medicines is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit frontier targets in RAS-addicted cancers. The companys R&D pipeline comprises RAS(ON) Inhibitors designed to suppress diverse oncogenic variants of RAS proteins and RAS Companion Inhibitors for use in combination treatment strategies. As a new member of the Revolution Medicines team you will join other outstanding Revolutionaries in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway.

The Opportunity:

The Executive Director Value Market Access & Pricing (GI) will lead the development and execution of European market access and pricing strategies for Revolution Medicines gastrointestinal oncology portfolio.

This role will be responsible for ensuring that payer HTA and policy requirements across Europe are fully embedded into product strategy evidence generation and launch planningwhile aligned with Global Value Access & Pricing strategies frameworks and governance.

Reporting to the VP Value Market Access & Pricing Europe the role serves as the primary European access strategy owner for GI partnering closely with Global Regional and Country teams to drive timely sustainable patient access across European markets.

Key Responsibilities

European Value Access & Pricing Strategy

• Lead and own theEuropean market access and pricing strategyfor GI indications with significant focus on PDAC ensuring optimal reimbursement and access outcomes across the EU and key European markets.

• Collaborate with Regional and Country Commercial Medical and Regulatory teams to shape the overall GI strategy projects and launch plans.

• Translateglobal value strategy Target Product Profiles (TPPs) and pricing principlesinto executable European access plans value dossiers and economic models while providing structured input to inform global strategy evolution.

• Shape and localize theEuropean value narrativefor GI ensuring alignment with the Global Value Dossier (GVD) and relevance to national HTA requirements.

• Define and executeEuropean launch sequencing net price corridors and reference pricing mitigation strategies in alignment with global pricing governance.

• Identify assess and proactively manageEurope-specific access risks and opportunitiesacross GI indications escalating insights to global and regional leadership as appropriate.

• Contribute to the JCA dossier in collaboration with the ED European JCA Oncology.

Evidence Generation & Development Alignment

• Partner withClinical Development HEOR Regulatory and Medical Affairsto ensure European payer and HTA evidence needs are embedded into GI development programs.

• Provide European leadership onstudy design endpoint selection comparators lines of therapy and sub-population strategiesto support successful HTA and reimbursement outcomes.

Launch Readiness & Market Execution

• LeadEuropean payer research and stakeholder engagement translating insights into actionable access strategies.

• Partner with regional and country teams to drivelaunch readiness including access roadmaps affiliate enablement and negotiation strategy support.

• Partner with regional and global commercial teams to contribute to forecasting and payer research.

Cross-Functional & Regional Leadership

• Serve as theEuropean access lead for GIon global asset and launch teams representing regional needs while reinforcing global alignment.

• Act as a strategic thought partner toCommercial Medical Regulatory HEOR and Global Access leadership on GI market dynamics and implications.

Policy Risk & External Engagement

• Monitor and assessEuropean pricing HTA and policy trendsrelevant to GI oncology translating implications into lifecycle and access strategies.

• Coordinate closely with Global and U.S. access teams to ensurepolicy and pricing alignment particularly where European decisions may impact global pricing corridors or lifecycle management.

Required Skills Experience and Education:

• Bachelors degree required; advanced degree inHealth Economics Pharmacy Life Sciences Public Health or Businesspreferred.

• 15 years of experiencein European market access pricing and HTA leadership within the biopharma or biotech industry.

• Proven success leadingEuropean launchesof specialty or oncology products including GI indications.

• Deep expertise inEuropean payer systems and HTA processes including AMNOG NICE HAS AIFA and EU-level HTA collaborations.

• Demonstrated ability to influenceclinical development and global strategythrough regional access insights.

• Strong track record of working effectively inmatrixed global organizations balancing regional accountability with global alignment.

Preferred Skills:

• EU market access experience with a strong focus ononcology.

• Experience supportingfirst-in-class or highly innovative therapies.

• Strong executive presence with the ability to clearly articulate complex value propositions to internal and external stakeholders.

Revolution Medicines takes protection and security of personal data very seriously and respects your right to privacy while using our website and when contacting us by email or phone. We will only collect process and use any personal data that you provide to us in accordance with ourCCPA additional information please contact.

#LI-Remote #LI-LO1